The trade name of the drug is Mirobivir. It is an analogue of Paxlovid manufactured by Pfizer and which presentation is film-coated tablets 150 mg + 100 mg
The drug will be produced at the Irkutsk manufacturing site of the Pharmasyntez Group of Companies and will enter civilian circulation next June.
Mirobivir is indicted for the treatment of the new mild or moderate coronavirus infection in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.
Nirmatrelvir blocks enzymes that viruses need to replicate thereby stopping virus reproduction process inside the cells. Ritonavir as a strong inhibitor of viral reproduction ensures necessary concentration of Nirmatrelvir in the body, improving therapy efficacy.
In February 2022, the Nirmatrelvir and Ritonavir combination was included by the Ministry of Healthcare of the Russian Federation in the 15th version of the Temporary Guidance “Prevention, Diagnostics and Treatment of the new coronavirus infection (COVID-19)”.
Thus, Pharmasyntez becomes a holder of practically complete portfolio of the drugs for the causal treatment of COVID-19: Remdeform (INN Remdesivir), Favibirin (INN Favipiravir), Covipir (INN Molnupiravir), and Mirobivir (INN Nirmatrelvir + Ritonavir).